SCH772984

目录号:S7101

SCH772984 Chemical Structure

Molecular Weight(MW): 587.67

SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。

规格 价格 库存 购买数量  
RMB 2210.07 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献15篇:

客户使用该产品的5个实验数据:

  • Immunoblot of H23 cells treated with trametinib (25 nM), SCH772984 (500 nM), or their combination for the times shown.

    Nature, 2016, 534(7609):647-51. SCH772984 purchased from Selleck.

    293T cells were transfected with Flag-WT-FBW7. Thirty hours post transfection, cells were pretreated with MG132 and various MEK/ERK inhibitors overnight before harvesting. FBW7 phosphorylation status was examined by immunoblot analysis after immunoprecipitation.

    Cell Research, 2015, 25: 561-573. SCH772984 purchased from Selleck.

  • Int J Oncol, 2018, 53(2):750-760. SCH772984 purchased from Selleck.

    K562 cells were exposed to ERK inhibitor SCH772984 (1 uM, 2 uM, 5 uM) for 48 h. Apoptosis was analyzed by Annexin V-APC labeling.

    Leuk Lymphoma 2014 1, 8. SCH772984 purchased from Selleck.

  • ERK1/2 influences the effects of TGF-β1 on Cdk5 and Bax in PC12 cells. A. Original western blot showing the level of Cdk5 and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. B. Arithmetic means ± SEM (n = 4) of Cdk5 protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) and LY294002(1.5 μM) for 2 h. C. Original western blot showing the level of Bax and respective Actin in PC12 cells with TGF-β1 (40 ng/ml) treatment in the presence of SCH772984(1 μM) for 2 h. D. Arithmetic means ± SEM (n = 4) of Bax protein abundance in PC12 cells with TGF-β1 treatment in the presence of SCH772984(1 μM) for 2 h. **(p < 0.01), ***(p < 0.001) indicate statistically significant difference.

    Biochem Biophys Res Commun, 2017, 485(4):775-781. SCH772984 purchased from Selleck.

产品安全说明书

ERK抑制剂选择性比较

生物活性

产品描述 SCH772984是一种新型特异性的ERK1/2抑制剂,无细胞试验中IC50分别为4 nM和1 nM, 对含有RAS或BRAF突变的癌细胞具有强大的功效。
特性 SCH772984不直接抑制MEK1, MEK2, BRAF, 或 CRAF酶活性。
靶点
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
体外研究

SCH772984是新型,选择性,ATP竞争性的ERK1/2抑制剂。SCH772984抑制ERK底物p90核糖体S6激酶(T359/S363 磷酸化-RSK)的磷酸化,这种作用存在剂量依赖性。SCH772984也能抑制ERK自身活化环中残基的磷酸化。SCH772984分别抑制约88%和49%BRAF突变型或RAS-突变型肿瘤细胞系,EC50值<500 nM。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 M12wWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHafHRKSzVyPUCuNlQhdk1? NYDTcWNOOjV|NUC5N|E>
WM-266-4 M4fhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLlTWM2OD1{MDDuUS=> MYOyN|YyPDh7OB?=
UACC-62 NYjrXXBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPCTWM2OD1|MDDuUS=> NGLqTIEzOzZzNEi5PC=>
Colo-205 NWry[G84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTnTZZrUUN3ME2zOkBvVQ>? M{O4T|I{PjF2OEm4
SK-Mel-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOzZno6UUN3ME2zO{BvVQ>? NIXEVHAzOzZzNEi5PC=>
WiDr NWfNXnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXvTWM2OD1|OTDuUS=> MmHVNlM3OTR6OUi=
M14 MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1Ttd2lEPTB;NEegcm0> MUGyN|YyPDh7OB?=
HT-29 NWjGSJpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVyIH7N MUWyN|YyPDh7OB?=
8505C NE\4[W5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL0TWM2OD13MDDuUS=> MV[yN|YyPDh7OB?=
HT-144 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTZyIH7N MlXVNlM3OTR6OUi=
SK-Mel-5 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInVNJhKSzVyPU[2JI5O M2PnOFI{PjF2OEm4
A375-SM MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWq2SJpNUUN3ME23OUBvVQ>? NFXxTHgzOzZzNEi5PC=>
SK-Mel-28 NEPrOHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrjTWM2OD16NTDuUS=> M13pZlI{PjF2OEm4
LOX NVTTOZY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFyMDDuUS=> NYS5cGRZOjN4MUS4PVg>
SK-Mel-3 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTSOZh1UUN3ME2xNVghdk1? NWTOTWxZOjN4MUS4PVg>
K1 M1\QXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF|MDDuUS=> NVjRbYNOOjN4MUS4PVg>
Hs-695T MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jIV2lEPTB;MU[1JI5O NWPrVYk{OjN4MUS4PVg>
BHT-101 NG\aeI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrvTWM2OD1|MECgcm0> NX24[ZpxOjN4MUS4PVg>
RPMI-7951 MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTN2NDDuUS=> NEK0[GkzOzZzNEi5PC=>
A2058 MnT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImwS3lKSzVyPUO2NEBvVQ>? MoTpNlM3OTR6OUi=
SK-Hep-1 NWrrdpplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvJVHpvUUN3ME2xOFIzKG6P MVyyN|YyPDh7OB?=
A673 NIHtcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH5TWM2OD1|MECxJI5O NXr4S5ZROjN4MUS4PVg>
DBTRG-05MG NF3KdYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nCRWlEPTB;M{CwNUBvVQ>? M2rFdVI{PjF2OEm4
SW-626 NEfscZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfMU3FPUUN3ME2zN{BvVQ>? MWOyN|YyPDh7OB?=
LoVo MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS1TWM2OD12NzDuUS=> MnjoNlM3OTR6OUi=
MiaPaCa MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoW2TWM2OD13MzDuUS=> MWqyN|YyPDh7OB?=
SW-620 MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;WN2pXUUN3ME2xNFQhdk1? M1\MSlI{PjF2OEm4
CAPAN-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXP[YVKSzVyPUGwOEBvVQ>? MVSyN|YyPDh7OB?=
SW-527 MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXsXpZKSzVyPUGyNUBvVQ>? NVLwXJZlOjN4MUS4PVg>
HCT-116 M{PGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LyZmlEPTB;MUK4JI5O MlnVNlM3OTR6OUi=
SW-480 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTF4NTDuUS=> NHPiT|YzOzZzNEi5PC=>
HPAC MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG1TWM2OD1zN{Cgcm0> M2iy[VI{PjF2OEm4
OVCAR-5 NYK5SJZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTVUYxsUUN3ME2yNFghdk1? MXyyN|YyPDh7OB?=
AsPc-1 NHG2clRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy4OWU1UUN3ME2yO|Ahdk1? MWiyN|YyPDh7OB?=
A549 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[0V3h4UUN3ME2zNlYhdk1? NXPSPIpPOjN4MUS4PVg>
SNU-1 NW\2UFZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrFT2V1UUN3ME2zOVQhdk1? NF30PWkzOzZzNEi5PC=>
HOP62 NXzzcYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTZ5NjDuUS=> NF\1VoozOzZzNEi5PC=>
H23 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFyMECgcm0> NXPxVGtsOjN4MUS4PVg>
MB-231 M2PDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXyTWM2OD1zMECwJI5O NXyzOmg{OjN4MUS4PVg>
SU.86.86 Mn3KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFyMEGgcm0> MmPqNlM3OTR6OUi=
CFPAC-1 M1\CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTFyMEGgcm0> Mn7oNlM3OTR6OUi=
A427 M3mzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrDdHJKSzVyPUG0N|Mhdk1? NGTldnYzOzZzNEi5PC=>
MDAH-2774 NFjKWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\YTWM2OD1{NkW3JI5O NVnUfYhXOjN4MUS4PVg>
NCI-H157 MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jydGlEPTB;M{CwNEBvVQ>? M1;3XVI{PjF2OEm4
HTB-177 NHH1Z2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoGxTWM2OD1|MECwJI5O MmTsNlM3OTR6OUi=
UM-UC-3 M3zKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzKTWM2OD1|MECxJI5O MkLmNlM3OTR6OUi=
HCT-8 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTNyMEGgcm0> NV6xOYU5OjN4MUS4PVg>
Panc-1 NILIeXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzkTWM2OD1|MECxJI5O NUnmSopIOjN4MUS4PVg>
DLD-1 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnOTWM2OD1|MECxJI5O MXqyN|YyPDh7OB?=
HCT-15 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTVTWM2OD1|MECxJI5O NUPRSXg3OjN4MUS4PVg>
HL-60 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7wXlZIUUN3ME2zNEBvVQ>? MXqyN|YyPDh7OB?=
SK-Mel-2 NHTIWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DrUGlEPTB;M{Sgcm0> NIjqOmEzOzZzNEi5PC=>
RD MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PvNmlEPTB;MUKzJI5O NIjqfm4zOzZzNEi5PC=>
HT-1197 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTNzNjDuUS=> MnXqNlM3OTR6OUi=
Molt-3 MoDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fHWWlEPTB;NkCwJI5O MVyyN|YyPDh7OB?=
PA-1 NI\ydWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z6TWlEPTB;MUCwNUBvVQ>? NFfVRVIzOzZzNEi5PC=>
Molt-4 MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{THUGlEPTB;M{CwNUBvVQ>? MmDiNlM3OTR6OUi=
NCI-H292 NGXkUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\6XVdIUUN3ME25NEBvVQ>? NY\OV2N2OjN4MUS4PVg>
A2780 NYq5SHA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF2MzDuUS=> NWXWdYJpOjN4MUS4PVg>
IGROV-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITvV3ZKSzVyPUG0OkBvVQ>? MYqyN|YyPDh7OB?=
SK-N-SH NYjicnBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv3TWM2OD1zNUCgcm0> MYOyN|YyPDh7OB?=
N-87 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTNyNzDuUS=> NXLvcmRkOjN4MUS4PVg>
H322 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLsW45{UUN3ME2zNlUhdk1? NXLPTYx[OjN4MUS4PVg>
H716 NFvpWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULDVJdIUUN3ME2zN|Qhdk1? NXTCfIh[OjN4MUS4PVg>
TT NWDY[llMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPKTWM2OD12ME[gcm0> NGnqWJUzOzZzNEi5PC=>
Caki-1 NFexVlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\TfY9mUUN3ME20OVAhdk1? M3rNTFI{PjF2OEm4
5637 NVnZbnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljaTWM2OD14MUCgcm0> NXvUXmR5OjN4MUS4PVg>
MB-453 NG\vZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jUXWlEPTB;NkeyJI5O NH7PfmwzOzZzNEi5PC=>
RT-4 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjOWVZpUUN3ME24NVAhdk1? M1\GOlI{PjF2OEm4
HOP92 NV\INYM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\kUGlEPTB;OEKwJI5O MWGyN|YyPDh7OB?=
KG-1 NFL1eJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTlyMDDuUS=> MWSyN|YyPDh7OB?=
Hs-294T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlv2TWM2OD17NEWgcm0> MnfaNlM3OTR6OUi=
SF-539 M1vpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTFyMECgcm0> NVrzdFlJOjN4MUS4PVg>
U-251 NULOR4l6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFyMECgcm0> MkDFNlM3OTR6OUi=
MB-468 M{TJUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu1VYFlUUN3ME2xNFAxKG6P MWOyN|YyPDh7OB?=
HS746T NEnMd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonjTWM2OD1zMECwJI5O M1LUeVI{PjF2OEm4
SCABER MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXKU24xUUN3ME2xNFAxKG6P NXXoW3g2OjN4MUS4PVg>
MCF-7 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFyMEGgcm0> MVqyN|YyPDh7OB?=
CHL-1 NYf6fGxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTF2NkCgcm0> M3ToeFI{PjF2OEm4
U87MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzob2dKSzVyPUKwNFAhdk1? MVGyN|YyPDh7OB?=
SJCRH30 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDZfnVKSzVyPUKwNFIhdk1? MX[yN|YyPDh7OB?=
ES-2 NV[1[lF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvHTWM2OD1{NkW5JI5O NGXNXZAzOzZzNEi5PC=>
HT-1376 M2noTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJ6MECgcm0> M2TKUVI{PjF2OEm4
A172 NUPsR3d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Ww[mlEPTB;M{CwNEBvVQ>? MnmzNlM3OTR6OUi=
769P MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTNyMECgcm0> MnmzNlM3OTR6OUi=
NCI-H520 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDubGlKSzVyPUOwNFAhdk1? M2Tj[VI{PjF2OEm4
DU145 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfqTWM2OD1|MECwJI5O MnzENlM3OTR6OUi=
K562 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\UeGJKSzVyPUOwNFAhdk1? NEKyTGkzOzZzNEi5PC=>
U-937 NGnCVohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV33fFBMUUN3ME2zNFAxKG6P NVftVHpuOjN4MUS4PVg>
A204 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXVTWM2OD1|MECxJI5O NHzMbo0zOzZzNEi5PC=>
DAOY NXnMRZBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP3TWM2OD1|MECxJI5O MWKyN|YyPDh7OB?=
SF-268 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDV[Y1tUUN3ME2zNFAyKG6P MmPjNlM3OTR6OUi=
SF-295 NHG4V2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDLeJVKSzVyPUOwNFEhdk1? MVqyN|YyPDh7OB?=
SNB-19 M2O3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTNyMEGgcm0> MnjlNlM3OTR6OUi=
SNB-75 M3P5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjzPJdbUUN3ME2zNFAyKG6P MnjqNlM3OTR6OUi=
U373-MG NWTwVox[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDOTWM2OD1|MECxJI5O MYSyN|YyPDh7OB?=
786-O M{\Ld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjhTXpYUUN3ME2zNFAyKG6P NW[2W3dOOjN4MUS4PVg>
A498 M{TseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfKOIJiUUN3ME2zNFAyKG6P MYWyN|YyPDh7OB?=
ACHN MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7hbWdFUUN3ME2zNFAyKG6P NVzQfY01OjN4MUS4PVg>
EKVX M{TlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:5TWM2OD1|MECxJI5O NGC4cVkzOzZzNEi5PC=>
H226 M1fnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DuPWlEPTB;M{CwNUBvVQ>? NUjG[W5OOjN4MUS4PVg>
H522 MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTNyMEGgcm0> NYrCXY5sOjN4MUS4PVg>
HeLa MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTNyMEGgcm0> MnPwNlM3OTR6OUi=
SK-OV-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHTTWM2OD1|MECxJI5O NX3SUYM3OjN4MUS4PVg>
Ln Cap NUDo[GdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fnNGlEPTB;M{CwNUBvVQ>? NWfMUoR3OjN4MUS4PVg>
PC3 NWHI[YZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vUeWlEPTB;M{CwNUBvVQ>? MYGyN|YyPDh7OB?=
SNU-16 M3nJbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnMc2wyUUN3ME2zNFAyKG6P NWqxS|QxOjN4MUS4PVg>
FTC-133 M3faNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLxZWxnUUN3ME2zNFAyKG6P MVqyN|YyPDh7OB?=
Ro82-W-1 M2CzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPYTWM2OD1|MECxJI5O MUeyN|YyPDh7OB?=
Daudi NE[1OVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNyMEGgcm0> NWixTYd5OjN4MUS4PVg>
Jijoye MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7GcnZZUUN3ME2zNFAyKG6P M2PHdFI{PjF2OEm4
Jurkat MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPyfo9YUUN3ME2zNFAyKG6P M4TmW|I{PjF2OEm4
J-82 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnhcmR3UUN3ME2zNFAyKG6P MYCyN|YyPDh7OB?=
TCC-SUP MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHMO4tKSzVyPUOwNFEhdk1? M{jN[lI{PjF2OEm4
BT-474 NYn4OWU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK3TYJ[UUN3ME2zNFAyKG6P M4CzNFI{PjF2OEm4
ZR-75-1 M{TNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTNyMEGgcm0> NV7Ncm1OOjN4MUS4PVg>

... Click to View More Cell Line Experimental Data

体内研究 SCH772984按耐受剂量处理移植瘤模型,诱导肿瘤衰退。SCH772984作用于抗BRAF或MEK抑制剂的模型,有效抑制MAPK信号和细胞增殖。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

ERK2 IMAP 酶实验:

SCH772984作用于纯化的ERK2或ERK1,按一式两份进行8点稀释曲线。酶添加到实验板中。与化合物温育,然后加入底物肽和ATP溶液中。384孔板中每孔加入14μl稀释的酶(每组反应含0.3ng活性ERK2)。实验板轻轻震荡混合试剂,然后在室温下温育45分钟。加入60μl of IMAP 结合溶液 (IMAP珠在1X结合缓冲液中按1:2200稀释)终止反应。实验板在室温下再温育0.5小时,使磷酸肽与IMAP珠完全结合。然后在 LJL分析仪上读数。
细胞实验:

[1]

+ 展开
  • Cell lines: BRAF突变型或 RAS突变型肿瘤系
  • Concentrations: ~10 μM
  • Incubation Time: 5 天
  • Method:

    在96孔板中进行细胞增殖实验,细胞按每孔 4,000个的密度接种。接种24小时后,使用DMSO处理细胞,9点IC50稀释 (0.001-10 μM) ,DMSO终浓度为1%。使用ViaLight发光试剂盒5天后,测定存活力。细胞系存活力检测中,使用SCH772984处理细胞4天,然后进行CellTiterGlo发光细胞活力检测。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 裸鼠
  • Formulation: --
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
0.6mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 587.67
化学式

C33H33N9O2

CAS号 942183-80-4
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • 回答:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: 购买SCH772984 | SCH772984供应商 | 采购SCH772984 | SCH772984价格 | SCH772984生产 | 订购SCH772984 | SCH772984代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID